{"anticipatedPostingDate":"2027-01","denomUnitsSelected":"Participants","description":"PFS along with the confidence intervals will be estimated using the Kaplan-Meier method.","reportingStatus":"NOT_POSTED","timeFrame":"From initiation of treatment to disease progression, disease recurrence, or death from any cause assessed up to 2 years","title":"Progression Free Survival (PFS) in Pediatric Patients Treated With Ulixertinib","type":"SECONDARY"}